Literature DB >> 16124066

Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study.

Hui Yue1, Hui-Yong Jiang.   

Abstract

AIM: To investigate the effects of p57(kip2), cyclinE protein and proliferating cell nuclear antigen (PCNA) on occurrence and progression of human pancreatic cancer.
METHODS: The expression of p57(kip2), cyclinE protein and PCNA in tumor tissues and adjacent tissues from 32 patients with pancreatic cancer was detected by SP immunohistochemical technique.
RESULTS: The positive expression rate of p57(kip2) protein in tumor tissues was 46.9%, which was lower than that in adjacent pancreatic tissues (chi(2) = 5.317, P<0.05). p57(kip2) protein positive expression remarkably correlated with tumor cell differentiation (P<0.05), but not with lymph node metastasis (P>0.05). The positive expression rate of cyclinE protein in tumor tissues was 68.8%, which was higher than that in adjacent pancreatic tissues (chi(2) = 4.063, P<0.05). CyclinE protein positive expression significantly correlated with tumor cell differentiation and lymph node metastasis (P<0.05). The positive expression rate of PCNA in the tumor tissues was 71.9%, which was higher than that in adjacent pancreatic tissues (chi(2) = 5.189, P<0.05). PCNA positive expression remarkably correlated with tumor cell differentiation and lymph node metastasis (P<0.05).
CONCLUSION: The decreased expression of p57(kip2) and/or overexpression of cyclinE protein and PCNA may contribute to the occurrence and progression of pancreatic cancer. p57(kip2), cyclinE protein, and PCNA play an important role in occurrence and progression of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16124066      PMCID: PMC4321930          DOI: 10.3748/wjg.v11.i32.5057

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Expression of second class of KIP protein p57KIP2 in human colorectal carcinoma.

Authors:  S Noura; H Yamamoto; M Sekimoto; I Takemasa; Y Miyake; M Ikenaga; N Matsuura; M Monden
Journal:  Int J Oncol       Date:  2001-07       Impact factor: 5.650

2.  Expression of p57/Kip2 protein in pancreatic adenocarcinoma.

Authors:  Y Ito; T Takeda; K Wakasa; M Tsujimoto; N Matsuura
Journal:  Pancreas       Date:  2001-10       Impact factor: 3.327

3.  Cyclin E and survival in patients with breast cancer.

Authors:  Khandan Keyomarsi; Susan L Tucker; Thomas A Buchholz; Matthew Callister; Ye Ding; Gabriel N Hortobagyi; Isabelle Bedrosian; Christopher Knickerbocker; Wendy Toyofuku; Michael Lowe; Thaddeus W Herliczek; Sarah S Bacus
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

4.  Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

Authors:  E Rosenberg; R I Demopoulos; A Zeleniuch-Jacquotte; H Yee; J Sorich; J L Speyer; E W Newcomb
Journal:  Hum Pathol       Date:  2001-08       Impact factor: 3.466

5.  Evaluation of proliferating markers Ki-67, PCNA in gastric cancers.

Authors:  J Czyzewska; K Guzińska-Ustymowicz; A Lebelt; B Zalewski; A Kemona
Journal:  Rocz Akad Med Bialymst       Date:  2004

6.  Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma.

Authors:  Yasuhiro Ito; Tsutomu Takeda; Yo Sasaki; Masato Sakon; Terumasa Yamada; Shingo Ishiguro; Shingi Imaoka; Masahiko Tsujimoto; Morito Monden; Nariaki Matsuura
Journal:  Liver       Date:  2002-04

7.  Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.

Authors:  M Kondo; S Matsuoka; K Uchida; H Osada; M Nagatake; K Takagi; J W Harper; T Takahashi; S J Elledge; T Takahashi
Journal:  Oncogene       Date:  1996-03-21       Impact factor: 9.867

8.  Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.

Authors:  I Orlow; A Iavarone; S J Crider-Miller; F Bonilla; E Latres; M H Lee; W L Gerald; J Massagué; B E Weissman; C Cordón-Cardó
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

9.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

Authors:  M H Lee; I Reynisdóttir; J Massagué
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

10.  Relationship between immunohistochemical evaluation of thymidylate synthase and proliferating cell nuclear antigen labeling index in gastrointestinal carcinoma.

Authors:  Yukihiro Kunimoto; Takeshi Nakamura; Masakazu Ohno; Yoshikazu Kuroda
Journal:  Oncol Rep       Date:  2004-12       Impact factor: 3.906

View more
  11 in total

1.  Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach.

Authors:  Daguang Wang; Fei Ye; Yabin Sun; Wei Li; Hongyi Liu; Jing Jiang; Yang Zhang; Chengkui Liu; Weihua Tong; Ling Gao; Yezhou Sun; Weijia Zhang; Terry Seetoe; Peng Lee; Jian Suo; David Y Zhang
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

2.  DNAse I pre-treatment markedly enhances detection of nuclear cyclin-dependent kinase inhibitor p57Kip2 and BrdU double immunostaining in embryonic rat brain.

Authors:  Weizhen Ye; Georges Mairet-Coello; Emanuel DiCicco-Bloom
Journal:  Histochem Cell Biol       Date:  2006-10-06       Impact factor: 4.304

Review 3.  Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Authors:  Mitra Zabihi; Ramin Lotfi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-04       Impact factor: 4.553

4.  Genomic landscape of meningiomas.

Authors:  Yohan Lee; Jason Liu; Shilpa Patel; Timothy Cloughesy; Albert Lai; Haumith Farooqi; David Seligson; Jun Dong; Linda Liau; Donald Becker; Paul Mischel; Soheil Shams; Stanley Nelson
Journal:  Brain Pathol       Date:  2009-11-20       Impact factor: 6.508

5.  Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a).

Authors:  Pinar Atasoy; Erdal Yilmaz; Onder Bozdogan; Sebnem Ayva; Ertan Batislam
Journal:  Int Urol Nephrol       Date:  2008-06-03       Impact factor: 2.370

6.  PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.

Authors:  Watcharin Loilome; Sasithorn Yooyuen; Nisana Namwat; Paiboon Sithithaworn; Anucha Puapairoj; Junko Kano; Masayuki Noguchi; Masanao Miwa; Puangrat Yongvanit
Journal:  Tumour Biol       Date:  2012-08-26

7.  Annexin A10 in human oral cancer: biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways.

Authors:  Toshihiro Shimizu; Atsushi Kasamatsu; Ayumi Yamamoto; Kazuyuki Koike; Shunsaku Ishige; Hiroaki Takatori; Yosuke Sakamoto; Katsunori Ogawara; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

Review 8.  Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Authors:  Marion Peyressatre; Camille Prével; Morgan Pellerano; May C Morris
Journal:  Cancers (Basel)       Date:  2015-01-23       Impact factor: 6.639

9.  Semaphorin7A Promotion of Tumoral Growth and Metastasis in Human Oral Cancer by Regulation of G1 Cell Cycle and Matrix Metalloproteases: Possible Contribution to Tumoral Angiogenesis.

Authors:  Tomoaki Saito; Atsushi Kasamatsu; Katsunori Ogawara; Isao Miyamoto; Kengo Saito; Manabu Iyoda; Takane Suzuki; Yosuke Endo-Sakamoto; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

10.  WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice.

Authors:  Chonji Fukumoto; Dai Nakashima; Atsushi Kasamatsu; Motoharu Unozawa; Tomomi Shida-Sakazume; Morihiro Higo; Katsunori Ogawara; Hidetaka Yokoe; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  Oncoscience       Date:  2014-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.